Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)

According to the data derived from several national and international registries, including SANI (Severe Asthma Network Italy), and considering the strong impact that frequent or regular use of oral corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs for managin...

Bibliografiset tiedot
Päätekijät:	Giorgio Walter Canonica, Francesco Blasi, Pierluigi Paggiaro, Gianenrico Senna, Giovanni Passalacqua, Antonio Spanevello, Stefano Aliberti, Diego Bagnasco, Marco Bonavia, Matteo Bonini, Luisa Brussino, Caterina Bucca, Maria F. Caiaffa, Cecilia Calabrese, Gianna Camiciottoli, Marco Caminati, Giovanna E. Carpagnano, Cristiano Caruso, Stefano Centanni, Maria E. Conte, Angelo G. Corsico, Lorenzo Cosmi, Maria T. Costantino, Nunzio Crimi, Simona D’Alò, Maria D'Amato, Stefano Del Giacco, Alessandro Farsi, Elisabetta Favero, Maria P. Foschino Barbaro, Gabriella Guarnieri, Giuseppe Guida, Manuela Latorre, Salvatore Lo Cicero, Carlo Lombardi, Luigi Macchia, Francesco Mazza, Francesco Menzella, Manlio Milanese, Marcello Montagni, Paolo Montuschi, Eleonora Nucera, Roberta Parente, Vincenzo Patella, Girolamo Pelaia, Laura Pini, Francesca Puggioni, Luisa Ricciardi, Fabio L.M. Ricciardolo, Luca Richeldi, Erminia Ridolo, Giovanni Rolla, Pierachille Santus, Nicola Scichilone, Giuseppe Spadaro, Andrea Vianello, Vittorio Viviano, Mona R. Yacoub, Maria C. Zappa, Enrico Heffler
Aineistotyyppi:	Artikkeli
Kieli:	English
Julkaistu:	Elsevier 2020-10-01
Sarja:	World Allergy Organization Journal
Aiheet:	Severe asthma Biologics Oral corticosteroids Real-life Registr
Linkit:	http://www.sciencedirect.com/science/article/pii/S1939455120303677

Samankaltaisia teoksia

Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey
Tekijä: Claudia Crimi, et al.
Julkaistu: (2023-11-01)

Economic impact of a more extensive use of FENO testing on the Italian population with asthma
Tekijä: Carla Rognoni, et al.
Julkaistu: (2023-06-01)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
Tekijä: Paolo Solidoro, et al.
Julkaistu: (2022-01-01)

Critical evaluation of asthma biomarkers in clinical practice
Tekijä: Giuseppe Guida, et al.
Julkaistu: (2022-10-01)

Nasal polyps impact in severe asthma patients: evidences from the SANI
Tekijä: Giorgio Walter Canonica, et al.
Julkaistu: (2020-08-01)

Asthma severity: the patient’s point of view
Tekijä: Gabriella Guarnieri, et al.
Julkaistu: (2024-12-01)

Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers
Tekijä: Giovanna Elisiana Carpagnano, et al.
Julkaistu: (2023-10-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
Tekijä: Diego Bagnasco, et al.
Julkaistu: (2021-02-01)

Severe asthma: One disease and multiple definitions
Tekijä: Diego Bagnasco, MD, PhD, et al.
Julkaistu: (2021-11-01)

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
Tekijä: Diego Bagnasco, et al.
Julkaistu: (2023-08-01)

Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort
Tekijä: Marco Caminati, MD, et al.
Julkaistu: (2024-08-01)

Phenotype overlap in the natural history of asthma
Tekijä: Fabio L.M. Ricciardolo, et al.
Julkaistu: (2023-05-01)

Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study
Tekijä: Paolo Solidoro, et al.
Julkaistu: (2019-04-01)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
Tekijä: Alessandra Vultaggio, et al.
Julkaistu: (2023-05-01)

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies
Tekijä: Giorgio Walter Canonica, et al.
Julkaistu: (2021-09-01)

Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)
Tekijä: Giorgio Walter Canonica, MD, et al.
Julkaistu: (2025-01-01)

Tezepelumab: patient selection and place in therapy in severe asthma
Tekijä: Francesco Menzella, et al.
Julkaistu: (2024-04-01)

Treatment strategies for asthma: reshaping the concept of asthma management
Tekijä: Alberto Papi, et al.
Julkaistu: (2020-08-01)

Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis
Tekijä: Maria D'Amato, et al.
Julkaistu: (2022-05-01)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
Tekijä: Giulia Scioscia, et al.
Julkaistu: (2020-03-01)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
Tekijä: Corrado Pelaia, et al.
Julkaistu: (2023-03-01)

Efficacy of Mepolizumab in patients with previous Omalizumab treatment failure: real life observation
Tekijä: Diego Bagnasco, et al.
Julkaistu: (2020-08-01)

The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Tekijä: Dejan Radovanovic, et al.
Julkaistu: (2017-05-01)

Vascular remodeling and TSLP/angiogenin overexpression in severe mixed asthma
Tekijä: Francesca Bertolini, et al.
Julkaistu: (2025-02-01)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
Tekijä: Erminia Ridolo, et al.
Julkaistu: (2020-10-01)

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside
Tekijä: Dejan Radovanovic, et al.
Julkaistu: (2017-06-01)

Is it severe asthma or asthma with severe comorbidities?
Tekijä: Brussino L, et al.
Julkaistu: (2017-11-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Tekijä: Giovanna Elisiana Carpagnano, et al.
Julkaistu: (2021-03-01)

Positioning tezepelumab for patients with severe asthma: from evidence to unmet needs
Tekijä: Carlo Lombardi, et al.
Julkaistu: (2024-11-01)

The extracellular matrix of the lung and airway responsiveness in asthma
Tekijä: F.G. Salerno, et al.
Julkaistu: (2016-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
Tekijä: Carlo Lombardi, et al.
Julkaistu: (2024-07-01)

Alexithymia and asthma: a systematic review
Tekijä: Orlando Silvestro, et al.
Julkaistu: (2023-08-01)

Interleukin-5 in the Pathophysiology of Severe Asthma
Tekijä: Corrado Pelaia, et al.
Julkaistu: (2019-12-01)

Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
Tekijä: Carpagnano GE, et al.
Julkaistu: (2019-03-01)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
Tekijä: Giorgio Walter Canonica, et al.
Julkaistu: (2018-11-01)

Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis
Tekijä: Filippo Rumi, et al.
Julkaistu: (2022-04-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
Tekijä: Andrea Portacci, et al.
Julkaistu: (2023-10-01)

Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis
Tekijä: Cristiano Caruso, et al.
Julkaistu: (2022-09-01)

Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Tekijä: Francesco Menzella, et al.
Julkaistu: (2022-11-01)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
Tekijä: Andrea Giovanni Ledda, et al.
Julkaistu: (2023-09-01)